


AD-A143 082 EVALUATION IN RHECUS MONKEYS OF A BIVALENT LIVE  
ATTENUATED DENGUE VACCINE CONTAINING TYPES 2 AND 4  
VIRUSES(U) PUERTO RICO UNIV SAN JUAN E KRAISELBURD  
UNCLASSIFIED JUN 84 DAMD17-83-C-3029

F/G 6/5

NL

12  
END  
06/08/84  
OTIC

C-84



MICROCOPY RESOLUTION TEST CHART  
NATIONAL BUREAU OF STANDARDS 1964 A

AD-A143 082

(102)

"Evaluation in Rhesus Monkeys of a Bivalent Live Attenuated Dengue Vaccine Containing Types 2 and and 4 Virusess"

Annual and Final Report

Edmundo Kraiselburd, Ph.D.

June 1984

Supported by

US Army Medical Research and Development Command  
Fort Detrick, Frederick, Maryland 21701

Contract No. DAMD17-83-C-3029

University of Puerto Rico  
Medical Sciences Campus, GPO Box 5067  
San Juan, Puerto Rico 00936

DTIC FILE COPY

DTIC  
ELECTED  
S JUL 12 1984 D  
D

DOD Distribution Statement

Approved for public release; distribution unlimited

The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

84 07 10 089

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
		AD-A143082
4. TITLE (and Subtitle) Evaluation in Rhesus Monkeys of a Bivalent Live Attenuated Dengue Vaccine Containing Types 2 and 4 Viruses.		5. TYPE OF REPORT & PERIOD COVERED Final (Dec. 1/84 - May 31/84)
7. AUTHOR(s) Edmundo Kraiselburd, Ph.D.		6. PERFORMING ORG. REPORT NUMBER DAMD17-83-C-3029
9. PERFORMING ORGANIZATION NAME AND ADDRESS University of Puerto Rico Medical Sciences Campus San Juan, Puerto Rico 00936		10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
11. CONTROLLING OFFICE NAME AND ADDRESS US Army Medical Research and Development Command Fort Detrick Frederick, Maryland 21701		12. REPORT DATE June 1984
14. MONITORING AGENCY NAME & ADDRESS(if different from Controlling Office)		13. NUMBER OF PAGES 6
		15. SECURITY CLASS. (of this report)
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report)  Approved for public release, distribution unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 20, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Continue on reverse side if necessary and identify by block number) DEN-2/S-1 Vaccine; DEN-4 Vaccine; Rhesus monkeys immunity.		
20. ABSTRACT (Continue on reverse side if necessary and identify by block number) The purpose of this study was to determine whether a bivalent (dengue-2-4) vaccine could confer immunity in rhesus monkeys against wild type virus infection →  Dengue antibody-free animals were s.c. inoculated with 0.5 ml of either DEN-2 ( $2.9 \times 10^3$ pfu/ml; $3.8 \times 10^6$ MID <sub>50</sub> /ML), DEN-4 ( $1.2 \times 10^3$ pfu/ml; $1.9 \times 10^4$ MID <sub>50</sub> /ml) or a 1:1 mixture of DEN-2 and 4 vaccines. Approximately six months after vaccination, animals were challenged with $10^4$ MID <sub>50</sub> (25 pfu) of wild type DEN-2 virus.		

DD FORM 1 JAN 73 EDITION OF 1 NOV 68 IS OBSOLETE

SECURITY CLASSIFICATION OF THIS PAGE (When Data Entered)

20. Abstract (cont.)

It was found that:

- 1.) DEN-2/S-1 animals showed an anamnestic response as well as undetectable viremia after challenge with w.t. DEN-2 virus. Divalent vaccinees also showed an anamnestic response after DEN-2 virus challenge.
- 2.) DEN-4 vaccine did not elicit a measurable immune response in 6/8 animals as judged by PRNT, augmented N tests and by DEN-2 challenge experiments. An anamnestic response was observed in 2/8 animals.
- 3.) N antibody levels of most of the vaccinated animals declined markedly on or before post vaccination day 150.
- 4.) Viral interference among the two different vaccine serotypes could not be demonstrated.

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail and/or Special
A/I	



Accomplishments: Dengue antibody-free animals were divided into four experimental groups. Group I (8 monkeys) were s.c. inoculated with 0.5 ml of a 1:1 diluted DEN-2/S-1 vaccine ( $2.9 \times 10^3$  pfu/ml;  $3.8 \times 10^6$  MID<sub>50</sub>/ml). Group II (8 monkeys) were inoculated with 0.5 ml of a 1:1 diluted DEN-4 vaccine ( $1.2 \times 10^3$  pfu /ml,  $1.9 \times 10^4$  MID<sub>50</sub>/ml). Group III (13 monkeys) were inoculated with a 1:1 mixture of DEN-2 and DEN-4 vaccines. Group IV consisted of uninoculated (control) monkeys. Experimental animal were bled on post infection days 30, 60, 90, 120, 150, and 177 and N antibody titers against DEN-2 and 4 viruses were determined. Results from these experiments are shown in table 1. It can be seen that 6/8 DEN-2/S-1 vaccinated but only 2/8 DEN-4 vaccinated monkeys showed antibody response against the homologous wild type virus. 7/13 and 2/13 group III monkeys showed N antibodies against homologous wild type DEN-2 and DEN-4 virus, respectively. A  $\chi^2$  test revealed that there was no statistically significant difference in seroconversion between monovalent and divalent vaccinees ( $p < 5\%$ ). This demonstrated that viral interference among the two different vaccine serotypes did not occur. In agreement with previous reports,(1) antibody levels of most of the vaccinated animals declined markedly on or before post vaccination day 150. PRNT's showed that the DEN-4 vaccine did not elicit a strong immune response in rhesus monkeys. This was in agreement with results obtained in WRAIR which showed that only 2/5 human volunteers seroconverted after DEN-4 Vaccination (Dr. W. Brandt, personal communication).

Six months after vaccination, all animals were challenged with 10,000 MID<sub>50</sub> (25 pfu; 1,000 monkey ID<sub>50</sub>) of DEN-2 (PR159) virus (see Table II, page VI-8). Post challenge viremia was detected in 3/4 group 4 (control) monkeys, 1/13 group 3 (divalent vaccinees) and 5/8 group 2 (DEN-4 vaccinees). No

Viremia was detected in group 1 (DEN-2 vaccinees).

As expected, all DEN-2 inoculated control animals showed a typical primary antibody response against DEN-2 virus. DEN-2/S-1 Vaccinees showed an anamnestic response against the challenge virus. This type of antibody response was also observed in 2/8 group 2 vaccinees and in all group 3 vaccinees. Therefore, although some animals failed to show a measurable primary antibody response after vaccination, challenge with w.t. DEN-2 showed that infection with vaccine did occur. We interpreted this data to mean that the standard PRNT used (2) was not the most sensitive assay to measure animal seroconversion. This hypothesis was tested in our laboratory using the "augmented" neutralizing antibody test. Using this test, we were able to show antibody response to homologous virus in sera taken from group 1 monkeys B851 and B853 and from group III monkeys B810, B817, B825, B806 and B804. Antibody titers ranged from 15 to 80 and were undetectable in some of the animals after post vaccination day 30. This test failed to reveal dengue 4 antibody titers in dengue-4 vaccinees which did not seroconvert, as measured by the standard PRN test.

In conclusion, these experiments showed that:

1. In agreement with previous work of Scot et al (1) DEN-2/S-1 vaccinated animals showed an anamnestic response as well as undetectable viremia after challenge with w.t. DEN-2 virus. Divalent vaccinees also showed an anamnestic response after DEN-2 virus challenge.
2. DEN-4 vaccine did not elicit a measurable immune response in 6/8 animals as judged by PRNT, augmented N tests and by DEN-2 challenge experiments. An anamnestic response was observed in 2/8 animals.
3. In agreement with previous reports, N antibody level of most of the vaccinated animals declined markedly on or before post vaccination day 150.
4. Viral interference among the two different vaccine serotypes could not be demonstrated.

TABLE I: ANTIBODY RESPONSE OF RHESUS MONKEYS VACCINATED WITH  
WRAIR STRAINS OF DENGUE VIRUS.

ANTIBODY TITERS ON POST-VACCINATION DAY										
Monkey Number	Vaccine Type	30	60	90	120	150	177			
B840	D2	40	86	68	27	<10	<10			
B851	D2	<10	<10	<10	<10	<10	<10			
B873	D2	<10	72	14	<10	<10	<10			
B814	D2	<10	14	84	74	80	18			
B837	D2	74	11	17	33	26	37			
B833	D2	40	160	80	150	159	320			
B853	D2	<10	<10	<10	<10	<10	<10			
B815	D2	<10	32	29	<10	<10	<10			
B802	D4	<10	20	17	<10	<10	<10			
B829	D4	<10	<10	<10	<10	<10	<10			
B812	D4	<10	<10	<10	<10	<10	<10			
B805	D4	<10	<10	<10	<10	<10	<10			
B826	D4	<10	<10	<10	<10	<10	<10			
B834	D4	<10	<10	<10	<10	<10	<10			
B838	D4	52	27	<10	<10	<10	<10			
B855	D4	<10	<10	<10	<10	<10	<10			
B811	D2+D4	18	<10	30	<10	230	<10	110	<10	220
B810	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
B813	D2+D4	<10	<10	72	<10	310	<10	380	<10	270
B822	D2+D4	115	<10	>160	<10	>160	<10	>160	<10	>160
B827	D2+D4	58	<10	>160	12	64	>40	50	27	58
B817	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
B852	D2+D4	<10	<10	>640	>40	>640	29	>640	<10	590
B835	D2+D4	11	<10	72	<10	120	<10	230	<10	125
B825	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
B845	D2+D4	<10	<10	135	<10	47	<10	15	<10	13
B836	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
B806	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
B804	D2+D4	<10	<10	<10	<10	<10	<10	<10	<10	<10
(All control monkeys)										
B832	Control									
B831	Control									
B839	Control									
B286	Control	<10	<10	<10	<10	<10	<10	<10	<10	<10
B311	Control									
B521	Control									
A962	Control									
A411	Control									

TABLE II

Viremia and Antibody Response of Vaccinated Rhesus Monkeys After Challenge With Wild Type  
Dengue-2 Virus

Monkey Number	Vaccine Type	PRNT(Aug. Test)* Seroconversion		Antibody titers on Challenge day (177 days)		Day of viremia (pfu/ml)	D-2 N titers on post challenge days		
		D-2	D-4	D-2	D-4		10	30	60
B840	D2	+	N.D.	<10	N.D.	-	86	>640	800
B851	D2	-(+)	N.D.	<10	N.D.	-	380	540	660
B873	D2	+	N.D.	<10	N.D.	-	18	>640	2000
B814	D2	+	N.D.	18	N.D.	-	300	700	70
B837	D2	+	N.D.	37	N.D.	-	500	>640	960
B833	D2	+	N.D.	320	N.D.	-	490	>640	440
B853	D2	-(+)	N.D.	<10	N.D.	-	>640	>640	1400
B815	D2	+	N.D.	<10	N.D.	-	28	>640	N.D.*
B802	D4	N.D.	+	<10	N.D.	6(7.5),7(5)	>640	>640	3100
B829	D4	N.D.	-(-)	<10	N.D.	-	<10	250	900
B812	D4	N.D.	-(-)	<10	N.D.	5(2.5),7(2.5),8(7.5)	<10	>640	1250
B805	D4	N.D.	-(-)	<10	N.D.	-	<10	350	640
B826	D4	N.D.	-(-)	<10	N.D.	-	<10	>640	620
B834	D4	N.D.	-(-)	<10	N.D.	6(2.5)	<10	>320	>1280
B838	D4	N.D.	+	<10	N.D.	6(30),7(17.5)	225	>640	1050
B855	D4	N.D.	-(-)	<10	N.D.	7(10)	<10	640	580
B811	D2+D4	+	-	96	N.D.	-	3000	>640	>2560
B810	D2+D4	-(+)	-(-)	<10	N.D.	-	320	>640	>2560
B813	D2+D4	+	-	200	N.D.	-	190	135	150
B822	D2+D4	+	-	500	N.D.	-	2800	>640	1800
B827	D2+D4	+	+	130	N.D.	-	>1280	>640	640
B817	D2+D4	-(+)	-(+)	<10	N.D.	-	520	>640	>2560
B852	D2+D4	+	+	880	N.D.	-	2000	>640	1000
B835	D2+D4	+	-	220	N.D.	-	>5120	>640	600
B825	D2+D4	-(+)	-(+)	<10	N.D.	-	245	>640	280
B845	D2+D4	+	-	10	N.D.	-	>160	>640	2560
B836	D2+D4	-(+)	-(-)	<10	N.D.	5(2.5),6(7.5)	270	>640	2300
B806	D2+D4	-(+)	-(-)	<10	N.D.	-	620	>640	>2560
B804	D2+D4	-(+)	-(-)	<10	N.D.	-	>640	>640	>2560
B286	Control	-	-	<10	<10	8(2.5)	<10	1300	>2560
B311	Control	-	-	<10	<10	8(7.5)	<10	640	115
B521	Control	-	-	<10	<10	6(10),7(25),8(5),9(2.5)	<10	>640	>2560
B311	Control	-	-	<10	<10	-	<10	>640	>2560
B832	Control	-	-	<10	<10	- (Uninfected)	<10	<10	<10
B831	Control	-	-	<10	<10	- (Uninfected)	<10	<10	<10
B839	Control	-	-	<10	<10	- (Uninfected)	<10	<10	<10
A962	Control	-	-	<10	<10	- (Uninfected)	<10	<10	<10

\*N.D.: This monkey died on post-challenge day 51 of reasons unrelated to dengue virus infection.

N.D.: Not done.

(+): \*Indicates seroconversion to homologous virus as determined by the augmented neutralization test.


List of References

1. Scott, R McN, Nisalak, A., Eckels, K.H., Tinglapong, M., Harrison, V.H., Gould, D.J., Chapple, F.E., and Russell, P.K.: Dengue 2 vaccine, viremia and immune response in rhesus monkeys. *Infect. Immun.* 27, 181-186, 1980.
2. Russell, P.K., Nisalak, A., Sukhavachana, P., and Vivona, S.: A plaque reduction test for dengue virus neutralizing antibodies. *J. Immunol.* 99, 285-790, 1976.
3. Sato, H., Albrecht, P., Krugman, S., and Ennis, F.: Sensitive neutralization test for Rubella antibody. *J. Clin. Microbiol.* 9, 259-264, 1979.
4. Asano, Y., Albrecht, P., Stagno, S. and Takahashi, M.: Potentration of neutralization of varicella-zoster virus by antibody to immunoglobulin. *J. Infect. Dis.* 146, 524-529, 1982.

**FOREWORD**

In conducting the research described in this report, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW Publication No. (NIH) 78-23, Revised 1978)








AD-A143 082      EVALUATION IN RHECUS MONKEYS OF A BIVALENT LIVE  
ATTENUATED DENGUE VACCINE CONTAINING TYPES 2 AND 4  
VIRUSES(U) PUERTO RICO UNIV SAN JUAN E KRAISELBURD  
UNCLASSIFIED      JUN 84 DAMD17-83-C-3029

2/2  
F/G 6/5

NL





**SUPPLEMENTARY**

**INFORMATION**



AD-A143082

**DEPARTMENT OF THE ARMY**

US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
FORT DETRICK, FREDERICK, MD 21701 5012

REPLY TO  
ATTENTION OF

SGRD-RMS

10 January 1985

Subject: Errata to Technical Report, ADA143082

Administrator  
Defense Technical Information Center  
ATTN: DTIC-DDAC, Mrs. Crumbacker  
Cameron Station  
Alexandria, VA 22304-6145

1. Reference:

a. Subject document, ADA143082, Final Report, Jun 84, for Contract No. DAMD17-83-C-3029.

b. Revised DD Form 1473 for subject document. (Incl 1)

2. Request that the following changes be made in the Technical Report database for the subject document:

a. As indicated in Block 5 of Inclosure 1 change the start date of period covered.

b. Add the entry that has been added to Block 10 of Inclosure 1.

3. If you require further information or have questions regarding this matter please contact Mrs. Jane Idoine of this office at Autovon 343-7253.

I Incl  
as

*Patricia Madigan*  
(Mrs.) Patricia A. Madigan  
Technical Review Group  
Scientific and Technical  
Information Division

Dr. Howard E. Noyes/WRAIR  
Mr. Danny Laspe/USAMRAA

REPORT DOCUMENTATION PAGE		READ INSTRUCTIONS BEFORE COMPLETING FORM
1. REPORT NUMBER	2. GOVT ACCESSION NO.	3. RECIPIENT'S CATALOG NUMBER
4. TITLE (Name of Report)  Evaluation in Rhesus Monkeys of a Bivalent Live Attenuated Dengue Vaccine Containing Types 2 and 4 Viruses.		5. TYPE OF REPORT & PERIOD COVERED  Final (Dec. 1/84 - May 31/84)
6. AUTHOR(s)  Edmundo Kraselbund, Ph.D.		7. PERFORMING ORG. REPORT NUMBER  DAMD17-83-C-3029
8. PERFORMING ORGANIZATION NAME AND ADDRESS University of Puerto Rico Medical Sciences Campus San Juan, Puerto Rico 00936		9. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS  62770A.3M162770A870.AA.007
10. CONTROLLING OFFICE NAME AND ADDRESS US Army Medical Research and Development Command Fort Detrick Frederick, Maryland 21701		11. REPORT DATE  June 1984
12. MONITORING AGENCY NAME & ADDRESS (if different from Controlling Office)		13. NUMBER OF PAGES  6
		14. SECURITY CLASS. (of this report)
		15a. DECLASSIFICATION/DOWNGRADING SCHEDULE
16. DISTRIBUTION STATEMENT (of this Report)  Approved for public release, distribution unlimited		
17. DISTRIBUTION STATEMENT (of the abstract entered in Block 30, if different from Report)		
18. SUPPLEMENTARY NOTES		
19. KEY WORDS (Sufficient in number and identity to allow recovery)		
DEB-2/B-1 Vaccine; DEB-4 Vaccine; Rhesus monkeys immunity.		
20. ABSTRACT (Sufficient in number and identity to allow recovery)		
The purpose of this study was to determine whether a bivalent (dengue-2-4) vaccine could confer immunity in rhesus monkeys against wild type virus infection.		
Dengue antibody-free animals were s.c. inoculated with 0.5 ml of either DEB-2 ( $2.2 \times 10^3$ pfu/ml; $3.8 \times 10^4$ MLD <sub>50</sub> /ml), DEB-4 ( $1.2 \times 10^3$ pfu/ml; $1.9 \times 10^4$ MLD <sub>50</sub> /ml) or a 1:1 mixture of DEB-2 and 4 vaccines. Approximately six months after vaccination, animals were challenged with $10^4$ MLD <sub>50</sub> (25 pfu/ml) wild type DEB-2 virus.		

